VEON’s Beeline to bring mobile AI technology to medical diagnostics and research

AMSTERDAM, 23 Aug 2021 / PRNewswire / – VEON SA. (NASDAQ: VEON) (Amsterdam: VEON), one of the world’s leading providers of connectivity and internet services, announces that its mobile operator in Russia, Beeline, collaborates with that of Russia Sechenov Medical University in what it expects to be the revolutionary use of artificial intelligence (AI) technology in diagnostic medicine.

Building on Beeline’s advanced AI capabilities, the partnership is pioneering the use of neural network pattern matching algorithms to enable early detection of damage in hip joints and to identify kidney disease. and potential cancers.

Beeline’s AI technology was originally developed to support the “Lisa Alert” project; an initiative to locate and rescue missing persons Russia. Lisa Alert uses advanced algorithms as part of a suite of technologies to locate individuals through drone imagery analysis. The same AI technology will now be provided to researchers Moscow-based at Sechenov Medical University, that of Russia largest research medical school.

“The technology developed by mobile operators now goes far beyond connectivity and encompasses applications that help people live longer and healthier lives,” said Aleksandr Torbakhov, CEO of Beeline. “The use of Beeline’s AI technology in medical diagnostics demonstrates the contribution that mobile operators can make in this vital area, and we are proud to be part of this initiative with Sechenov Medical University.”

Under the agreement, Beeline and Sechenov Medical University will develop AI software and data analytics to provide early diagnosis of critical diseases and conditions in trauma and histology. AI software is used to analyze MRI images and helps physicians accurately diagnose and identify the development of pathologies, which is especially critical at an early stage of disease development.

In trauma, this will include the use of AI to detect pathologies of the hip joint to allow medical and non-surgical treatment at an early stage. AI analysis also helps doctors identify conditions such as synovitis, cartilage damage, and pathological changes in subchondral structures.

In histology, the AI ​​algorithm allows clinicians to classify tissues in histological sections during kidney and intestinal biopsies. This helps medical research activities by reducing analysis time while decreasing the risk of errors. AI pattern recognition is also intended for use in oncology where it will analyze the influence of certain tissue formations as predictors of kidney cancer, and thus potentially allow early diagnosis.

“Medicine is a new and very interesting field of research in terms of information technology”, explains George held, director of the digital operator of the VEON group. “In cooperation with Sechenov University, we plan to create breakthrough products based on artificial intelligence and big data analysis that will enable healthcare professionals to speed up diagnoses and make their jobs easier. We are convinced that our cooperation will help save lives and stop development. serious illnesses. “

About VEON

VEON is a global connectivity and digital services provider listed on NASDAQ and Euronext Amsterdam. Our businesses are transforming lifestyles with technology-driven services that provide opportunities in some of the world’s fastest growing emerging markets. For more information visit:https://www.veon.com

Disclaimer

This press release contains “forward-looking statements” as defined in Section 27A of the US Securities Act of 1933, as amended, and Section 21E of the US Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts and include statements relating, among other things, to expectations regarding the benefits of AI technology in diagnostic medicine. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with precision and some of which may not even be anticipated by VEON. The forward-looking statements contained in this press release speak only as of the date of this press release. VEON does not undertake to publicly update, except as required by US federal securities laws, any forward-looking statements to reflect events or circumstances after these dates or to reflect the occurrence of unforeseen events.

Contact details:

Communication & Investor Relations
Nik Kershaw
[email protected]
+31 20 79 77 200

SOURCE VEON SA


Source link